Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nippon Shinyaku Grabs Rights to Regenxbio’s MPS Gene Therapies
Nippon Shinyaku said on January 14 that it has sealed a deal with Regenxbio to in-license the US biotech’s gene therapies RGX-121 and RGX-111 for the treatment of mucopolysaccharidosis (MPS) in the US and Asia. RGX-121 is being developed for…
To read the full story
Related Article
- Regenxbio Appeals FDA CRL for MPS II Gene Therapy RGX-121
May 18, 2026
- FDA Rejects Regenxbio/Nippon Shinyaku’s MPS II Gene Therapy
February 12, 2026
- FDA Places Clinical Hold on MPS Gene Therapies: Regenxbio/Nippon Shinyaku
January 30, 2026
- FDA Pushes Back Decision on Hunter Syndrome Gene Therapy
August 20, 2025
BUSINESS
- Takeda’s Zasocitinib Beats Sotyktu in PIII Psoriasis Trial
June 15, 2026
- Rakuten Medical CEO-Elect Reaffirms 2028 US Filing Plan for Akalux
June 15, 2026
- Heartseed Starts Japan PI/II of Catheter-Delivered iPSC Cardiomyocyte Therapy
June 15, 2026
- Lilly Breaks Ground on New Building at Kobe Plant
June 15, 2026
- Shionogi Invests in Reproductive Medicine Startup Dioseve
June 15, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…